A phase II study of pemetrexed monotherapy in chemo-na < ve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

Hata Akito; Katakami Nobuyuki; Fujita Shiro; Nanjo Shigeki; Takeshita Jumpei; Tanaka Kosuke; Kaneda Toshihiko; Nishiyama Akihiro; Nishimura Takashi; Nakagawa Atsushi; Otsuka Kojiro; Morita Satoshi; Urata Yoshiko; Negoro Shunichi

首页> 外文期刊>Cancer chemotherapy and pharmacology. >A phase II study of pemetrexed monotherapy in chemo-na < ve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

【24h】

A phase II study of pemetrexed monotherapy in chemo-na < ve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

机译：培美曲塞单药治疗东部化疗合作组II状态临床研究2例EGFR野生型或未知晚期非鳞状非小细胞肺癌患者（HANSHIN Oncology Group 002）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The aim of our study was to investigate the efficacy and safety of pemetrexed monotherapy in chemo-na < ve Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 patients with epidermal growth factor receptor (EGFR) wild-type or unknown advanced non-squamous non-small cell lung cancer (NSCLC).

机译：我们的研究目的是研究培美曲塞单药在东方合作化疗组（ECOG）2例具有表皮生长因子受体（EGFR）野生型或未知晚期非临床表现的患者中的疗效和安全性-鳞状非小细胞肺癌（NSCLC）。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2015年第6期|共6页
作者
Hata Akito; Katakami Nobuyuki; Fujita Shiro; Nanjo Shigeki; Takeshita Jumpei; Tanaka Kosuke; Kaneda Toshihiko; Nishiyama Akihiro; Nishimura Takashi; Nakagawa Atsushi; Otsuka Kojiro; Morita Satoshi; Urata Yoshiko; Negoro Shunichi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Pemetrexed; Eastern Cooperative Oncology Group performance status 2; Epidermal growth factor receptor gene wild-type; Non-squamous non-small cell lung cancer;

机译：培美曲塞;东部合作肿瘤小组工作状态2;表皮生长因子受体基因野生型;非鳞状非小细胞肺癌;

相似文献

外文文献
中文文献
专利

1. A phase II study of pemetrexed monotherapy in chemo-na < ve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002) [J] . Hata Akito, Katakami Nobuyuki, Fujita Shiro, Cancer chemotherapy and pharmacology. . 2015,第6期

机译：培美曲塞单药治疗东部化疗合作组II状态临床研究2例EGFR野生型或未知晚期非鳞状非小细胞肺癌患者（HANSHIN Oncology Group 002）
2. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. [J] . Mauro Zukin, Carlos H Barrios, Jose Rodrigues Pereira, Journal of Clinical Oncology . 2013,第23期

机译：培美曲塞单药与卡铂和培美曲塞单药治疗晚期非小细胞肺癌和东部合作肿瘤小组患者的状态为2的随机III期试验。
3. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. [J] . Mauro Zukin, Carlos H Barrios, Jose Rodrigues Pereira, Journal of Clinical Oncology . 2013,第23期

机译：单孕术治疗单孕二酮的随机期III试验与晚期非小细胞肺癌和东方合作肿瘤患者的患者患者2。
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab cixutumumab or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508) [O] . Nasser H. Hanna, Suzanne E. Dahlberg, Jill Kolesar, -1

机译：三臂卡铂和紫杉醇联合西妥昔单抗西妥昔单抗或两者联合用于不接受贝伐单抗治疗的晚期非小细胞肺癌（NSCLC）患者的三臂随机II期研究：东方合作肿瘤小组（ECOG）研究（E4508）
7. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2 [O] . David R. Spigel, John D. Hainsworth, Mathew J. Joseph, 2018

机译：在IIIB / IV非小细胞肺癌患者和东方合作肿瘤患者中，培养基，聚光磷酸盐/贝伐单抗和磷酸盐/卡铂/贝伐单抗的随机阶段2试验及2

A phase II study of pemetrexed monotherapy in chemo-na < ve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

摘要

著录项

相似文献

相关主题

期刊订阅